This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Assistance Publique-Hopitaux De Paris, Iltoo Pharma, National Institute of Health and Medical Research. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:


Years Active: 2025
Title: Encarnita Mariotti-Ferrandiz: Innovator in Immunotherapy
Introduction
Encarnita Mariotti-Ferrandiz is a notable inventor based in Paris, France. He has made significant contributions to the field of immunotherapy, particularly in the treatment of autoimmune and inflammatory disorders. His innovative work has led to the development of a unique combination therapy that leverages the properties of interleukin-2 and interleukin-1 inhibitors.
Latest Patents
Encarnita holds 1 patent for his invention titled "Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof." This patent describes a combination of interleukin-2 (IL-2) and an interleukin-1 (IL-1) inhibitor, aimed at treating autoimmune and inflammatory disorders in subjects. The invention also includes a pharmaceutical composition that comprises both IL-2 and an IL-1 inhibitor, as well as a conjugate that features IL-2 conjugated to an IL-1 inhibitor.
Career Highlights
Throughout his career, Encarnita has worked with prominent organizations such as Iltoo Pharma and Sorbonne Université. His work in these institutions has allowed him to advance his research and contribute to the scientific community significantly.
Collaborations
Encarnita has collaborated with esteemed colleagues, including David Klatzmann and Jérémie Mariau. These partnerships have enriched his research and fostered innovation in the field of immunotherapy.
Conclusion
Encarnita Mariotti-Ferrandiz is a pioneering inventor whose work in immunotherapy has the potential to transform treatment options for autoimmune and inflammatory disorders. His contributions to science and medicine are noteworthy and continue to inspire future innovations.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile